Stepping down deliberately, and how to do it without losing progress — what changed since posts 31–60

The four-week step is a trial convention, not a pharmacological constant. It is roughly four half-lives for a week-long half-life, which is the interval at which you are assessing a stable concentration rather than a rising one.

Answering the question post #42 raises rather than the one it answers.

Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.

That is the shape of it. The detail is where I would expect to be corrected.

Splitting a weekly dose in two: the pharmacokinetic argument against is that you want the benefit of long half-life, which gives a slowly changing plasma level from a weekly dosing schedule. Splitting it flattens the curve further but loses the convenience of once-weekly dosing. The trade-off is convenience versus a slightly flatter concentration curve.

Stating my assumptions rather than smuggling them in.

This settles it for me, at least until somebody posts a reason it should not.

Escalating before steady state means you are judging a dose you have not yet fully experienced. That is the whole argument against compressing the schedule and it is a good one.

Post #50 and I disagree about the size of the effect, not about the direction.

Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.

That is my reading. Someone else read the same page differently and was reasonable.

Taking post #50 at face value and following it one step further.

The most common practical error is not the schedule at all — it is losing track of which step you are on after a break, and then resuming at the top rather than re-approaching it.

Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.

I would put a moderate confidence on that and no more.

Reaching a dose and staying there for a year: the question of whether a stable dose remains effective over years is mostly answered by the withdrawal trials and by real-world reports. The dose does not seem to stop working, but the longest trials are not indefinitely long.

I checked the source rather than the summary, and they differ.

Building on post #53 rather than restating it.

The starting dose in most of these programmes is a tolerance step and produces little effect by design. Judging the compound at the starting dose is judging the wrong thing.

The reasoning is more useful than the number, which is why I have shown it.

Following, with nothing to contribute beyond having asked the same thing elsewhere.

Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.

The maximum studied dose is a fact about the trial and not a ceiling on the molecule. It is also the last point at which anything is known, which is the reason to treat it as one.

Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.

I have left out the parts I could not verify.